Amicus Therapeutics (FOLD) announced negative results Wednesday from a late-stage clinical trial of an experimental topical medicine for patients suffering from a rare, inherited skin-blistering disease.

In the phase 3 clinical trial, the Amicus drug SD-101 did no better than placebo in healing wounds in patients with epidermolysis bullosa.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.